Evaluation the Safety of hemay005 Tablets

NCT06908642 | Completed Phase 1

• 1 other identifier: HM005CO1S01
• Study Type: interventional
• Target: 468
• Locations: 1 country
• Sites: 1

Brief Summary

Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.

Conditions

Chronic Obstructive Pulmonary Disease

Outcome Measures

Primary Outcomes (1)

• Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.

  Number of Participants With Treatment-Related Adverse Events as Assessed by Grade of Adverse Event

  14 Days

Study Arms (7)

0-45mg Hemay005

ACTIVE COMPARATOR

By using titration method, the dosage of the drug was gradually increased from 0 to 45 mg BID for 14 days

Drug: Hemay005 tablet

45mg Hemay005

ACTIVE COMPARATOR

The subjects took the medicine twice a day, 45 mg each time, for 14 days.

Drug: Hemay005 tablet

0-60mg Hemay005

ACTIVE COMPARATOR

By using titration method, the dosage of the drug was gradually increased from 0 to 60 mg BID for 14 days

Drug: Hemay005 tablet

60mg Hemay005

ACTIVE COMPARATOR

The subjects took the medicine twice a day, 60 mg each time, for 14 days.

Drug: Hemay005 tablet

0-75 mg Hemay005

ACTIVE COMPARATOR

By using titration method, the dosage of the drug was gradually increased from 0 to 75 mg BID for 14 days

Drug: Hemay005 tablet

75 mg Hemay005

ACTIVE COMPARATOR

The subjects took the medicine twice a day, 75 mg each time, for 14 days.

Drug: Hemay005 tablet

placebo

PLACEBO COMPARATOR

The subjects took the medicine twice a day. In the first week, they took placebos; in the second week, they took 60 mg hemay005 each time, for a total of 14 days of medication.

Drug: Placebo

Interventions

Placebo DRUG

Placebos are the same as drugs, but contain no Hemay005.

placebo

Hemay005 tablet DRUG

Hemay005 is a small molecule PDE4 inhibitor.

0-45mg Hemay005; 0-60mg Hemay005; 0-75 mg Hemay005; 45mg Hemay005; 60mg Hemay005; 75 mg Hemay005

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \) Male and female subjects aged 18 to 65 years old (inclusive of 18 and 65);
• \) Weight: Male should be no less than 50.0 kg, female no less than 45.0 kg. Body Mass Index (BMI) \[ = weight (kg) / height2 (m2) \] should be within the range of 18.5 to 30.0 kg/m2 (inclusive of boundary values);
• \) Before the trial, they have been thoroughly informed about the nature, significance, possible benefits, as well as possible inconveniences and potential risks of the trial, and have voluntarily participated in this clinical trial. They can communicate well with the researchers, comply with all requirements of the entire study, and have signed a written informed consent form.

You may not qualify if:

• \) Participants who have participated in other drug/medical device trials within the previous 3 months (based on the use of the trial drugs/medical devices);
• \) Those with clinical manifestations of abnormalities that need to be excluded, including but not limited to diseases in the nervous system, cardiovascular system, hematological and lymphatic system, immune system, kidneys, liver, gastrointestinal tract, respiratory system, metabolism and bone system;
• \) Those with specific allergy histories (asthma, urticaria, eczema, etc.), or with allergic constitution (such as those allergic to two or more drugs, foods or pollen), or those known to be allergic to this product;
• \) Participants who have lost or donated blood exceeding 400ml within the previous 3 months, or those who plan to donate blood during the trial;
• \) Pregnant or lactating women, or those who have a fertility plan or donation plan for sperm or eggs within two weeks before the trial or within 3 months after the last administration, and are unwilling or have not taken effective contraceptive measures;
• \) General physical examination, vital signs, laboratory tests (blood routine, blood biochemistry, coagulation function, urine routine, hepatitis B and C, AIDS, syphilis, and HIV tests, pregnancy test for females, etc.) within the previous 7 days before randomization; electrocardiogram results within the previous 14 days before randomization judged by clinical doctors as abnormal with clinical significance; chest X-ray results within the previous 3 months before randomization judged by clinical doctors as abnormal with clinical significance;
• \) Alcohol breath test results greater than 0.0mg/100ml or positive results in drug abuse screening;
• \) Those who have a history of severe vomiting or diarrhea within the previous 7 days or any other diseases or physiological conditions that may interfere with the test results;
• \) Those who have suffered from major clinical diseases or undergone major surgical operations within 3 months before screening;
• \) Those who consume more than 14 units of alcohol per week (1 unit = 17.7 mL ethanol, which is equivalent to 357 mL of 5% alcohol beverage, 43 mL of 40% alcohol liquor, or 147 mL of 12% wine) within 3 months before screening, or those who cannot abstain from alcohol during the test;
• \) Those who smoke more than 5 cigarettes per day on average within 3 months before screening, or those who cannot stop using any tobacco products during the test;
• \) Those who consume excessive tea, coffee and/or beverages rich in caffeine (more than 8 cups, 1 cup = 250 mL) every day within 3 months before screening.
• \) Exclude those who have used any drugs that inhibit or induce liver drug-metabolizing enzymes within the past 30 days (such as inducers - barbiturates, carbamazepine, phenytoin, glucocorticoids; inhibitors - SSRI class antidepressants, cimetidine, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines).
• \) Those with a history of tuberculosis or those with active tuberculosis during the screening period;
• \) Those who are unable to eat or have difficulty swallowing;

Sponsors & Collaborators

• Anhui Hemay Pharmaceutical Co., Ltd: lead

Study Sites (1)

The Second Affiliated Hospital of Wannan Medical College

Wuhu, Anhui, 241000, China

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Hemay005

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 18, 2025
• First Posted: April 3, 2025
• Study Start: December 25, 2024
• Primary Completion: June 3, 2025
• Study Completion: June 3, 2025
• Last Updated: December 9, 2025

Record last verified: 2025-06

Locations

CN (1)